2027 Medicare Lab Fee Schedule Cuts: How Labs Are Preparing Before AMP 2026

The October issue of Laboratory Economics led with the number lab leaders have been bracing for: an average weighted cut of 16% in CMS's preliminary 2027 CLFS rates. With final rates due in November and the molecular community meeting in Seattle for AMP 2026 (#AMP2026) the same month, the cuts will be the topic on the expo floor.

How much will Medicare cut lab payments in 2027?

CMS released the preliminary rates on September 21, built from private payer data labs reported between May and July of this year. The average weighted cut is 16%. Of the codes CMS was able to price, 1,171 came in below their 2026 rates, 186 came in higher and 169 held steady.

By law, no single code can drop more than 15% in a year. Codes with deeper calculated cuts will step down over 2027, 2028 and 2029. Rates and supporting files are on the CMS Clinical Laboratory Fee Schedule page.

Which labs will feel the cuts most?

Independent labs with heavy Medicare volume carry the most exposure, and Laboratory Economics singled out independent nursing home labs as especially hard hit. Molecular labs face a second pressure: Medicare Part B volume for 37 PCR-based microbiology codes, excluding COVID, fell 3% to 24.6 million tests in 2025 after years of double-digit growth. RSV PCR alone dropped 37%. Lower rates on flat or falling volume squeezes margin fast.

The impact can also reach beyond traditional Medicare. Medicare Advantage and commercial contracts pegged to the CLFS can reset with it.

How is the lab community responding?

• Challenging the data. Industry groups point out that only about 2% of labs paid under Medicare Part B reported data, which they say gives an incomplete picture of the market.
• Capitol Hill advocacy. AMP brought clinical lab leaders to Washington in May to meet with more than 30 congressional offices.
• Formal comments. The AHA filed comments with CMS on October 21, urging the agency to use its existing flexibility to soften the cuts and correct data errors on certain codes.
• A year-end push. Industry groups have said they aim to attach the RESULTS Act to a year-end spending package, the same kind of vehicle that delayed the cuts for 2026.

CMS has framed the update as bringing Medicare in line with what private insurers pay for the same tests.

What is the RESULTS Act, and will it pass before January 1?

The RESULTS Act (H.R. 5269 / S. 2761) is a bipartisan bill that would freeze CLFS rates for 2027 and 2028, then set 2029 rates from an independent commercial claims database instead of lab self-reporting. It has broad support from lab and provider groups but has not passed. Labs should plan for both outcomes.

What can labs do before the 2027 cuts take effect?

Advocacy may soften the cuts. It will not fix leakage inside the revenue cycle. These are the areas worth tightening now:

• Model your top-code exposure. Run your 20 highest-volume codes against the preliminary rates and see what 2027 looks like at current volume.
• Check contracts tied to CLFS. Identify which payer contracts reference the Medicare fee schedule and will reset with it.
• Chase underpayments. When rates drop, every claim paid below the contracted amount hurts more. Audit remits against contract terms and appeal the gaps.
• Keep MolDX and Z-code registrations current. A missing or outdated registration can deny every claim on a panel, regardless of the rate.
• Work denials by root cause. Medical necessity and LCD/NCD coverage, NCCI bundling edits and timely filing are where most recoverable lab revenue sits. Fix the pattern upstream so it stops repeating.
• Secure authorization up front. For tests that require prior authorization, confirm it before the specimen runs. It cannot be recovered after the fact.

Not sure where your lab stands? The ADS lab team will run these checks with you in a free 15-minute review. Book my review →

For a deeper planning checklist, read PAMA Reporting Is Over: How Independent Laboratories Can Prepare for 2027.

Meet the ADS lab team at AMP 2026, Booth #1901

The Association for Molecular Pathology's AMP 2026 Annual Meeting and Expo runs November 10 to 14 at the Seattle Convention Center, with more than 200 exhibitors and sessions on the policy, regulatory and billing changes affecting molecular diagnostics. Jim O'Neill, Laboratory Services Business Development Manager, and Gene Spirito, VP Sales and Business Development, will be at ADS Booth #1901.

Bring your top codes and your denial reports. The team will walk through your 2027 exposure and where your claims are getting stuck. Booth time fills up, so use the form below to reserve 15 minutes in Seattle. Getting ready for the show? See the five billing questions molecular labs should bring to AMP.

Want the benchmarks first? Download the free State of Lab Revenue Report.

ADS has supported specialty billing for 49 years, and our laboratory billing services and software are built around lab-specific rules, not general medical billing.

Frequently asked questions

When do the 2027 Medicare lab fee schedule cuts take effect?

January 1, 2027. CMS released preliminary rates on September 21, 2026 and expects to finalize them in November 2026.

How large are the 2027 CLFS cuts?

The preliminary rates average a 16% weighted cut. Each code can drop no more than 15% per year, so some codes will see additional cuts in 2028 and 2029.

Will the RESULTS Act stop the 2027 cuts?

If enacted, the RESULTS Act would freeze CLFS rates for 2027 and 2028 and change how future rates are calculated. It has bipartisan support but had not passed as of late October 2026.

Do CLFS cuts affect commercial and Medicare Advantage contracts?

They can. Any payer contract that pays as a percentage of the Medicare fee schedule will move with the new rates.

Where is ADS at AMP 2026?

ADS is at Booth #1901 at the Seattle Convention Center, November 10 to 14, 2026. Labs can reserve a meeting with Jim O'Neill and Gene Spirito using the form on this page.